Suberoylanilide hydroxamic acid represses glioma stem-like cells

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Epigenetics

Background:

• Glioblastoma multiforme (GBM) exhibits high treatment resistance, often attributed to glioma stem-like cells (GSCs).
• Histone deacetylase (HDAC) activity is implicated in cancer stem-like cell (CSC) properties and abundance.
• Investigating novel therapeutic strategies to target GSCs is crucial for improving GBM patient outcomes.

Purpose of the Study:

• To investigate the effects of suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor, on GSCs.
• To elucidate the mechanism by which SAHA modulates GSC stemness and viability.
• To assess SAHA's potential in overcoming therapeutic resistance in GBM.

Main Methods:

• Human GBM cell lines were cultured in serum-free conditions to enrich for GSCs.
• GSCs were treated with SAHA, and subsequent analyses included stemness markers, proliferation, viability, apoptosis, and senescence.
• Key molecular pathways, including caspase activation, p53, and p38, were examined.

Main Results:

• SAHA treatment significantly attenuated GSC proliferation and reduced expression of stemness markers (CD133, Bmi1).
• High SAHA concentrations induced GSC apoptosis via caspase 8 and 9 activation.
• Lower SAHA doses triggered cell cycle arrest and premature senescence, involving p53 up-regulation and p38 activation.

Conclusions:

• SAHA effectively induces apoptosis and modulates senescence in GSCs through the p38-p53 pathway.
• SAHA demonstrates potential as a therapeutic agent for targeting GSCs in GBM.
• These findings suggest SAHA could be a valuable strategy to overcome drug resistance in glioblastoma patients.